IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will feature a fireside chat with Yujiro S. Hata, CEO of IDEAYA, hosted by Judah Frommer, Executive Director and Senior Equity Research Analyst at Morgan Stanley.
The conference is scheduled for Wednesday, September 4th, 2024 at 5:35 PM ET. Investors and interested parties can access a live audio webcast of the event through the 'Investors/Events' section of IDEAYA's website or via the conference host. The webcast replay will be available for 30 days following the live event, providing an opportunity for those unable to attend to catch up on the discussion.
IDEAYA Biosciences (NASDAQ: IDYA), una compagnia di oncologia di medicina di precisione, ha annunciato la sua partecipazione alla 22a Conferenza Annuale Globale sulla Sanità di Morgan Stanley. L'evento presenterà una chiacchierata informale con Yujiro S. Hata, CEO di IDEAYA, moderata da Judah Frommer, Direttore Esecutivo e Analista Senior di Ricerca Azionaria presso Morgan Stanley.
La conferenza è programmata per mercoledì 4 settembre 2024 alle 17:35 ET. Gli investitori e le parti interessate possono accedere a una trasmissione audio in diretta dell'evento attraverso la sezione 'Investitori/Eventi' del sito web di IDEAYA o tramite l'host della conferenza. La registrazione della trasmissione sarà disponibile per 30 giorni dopo l'evento dal vivo, offrendo così l'opportunità a chi non è riuscito a partecipare di seguire la discussione.
IDEAYA Biosciences (NASDAQ: IDYA), una empresa de oncología de medicina de precisión, ha anunciado su participación en la 22ª Conferencia Global Anual de Salud de Morgan Stanley. El evento contará con una charla junto a la chimenea con Yujiro S. Hata, CEO de IDEAYA, moderada por Judah Frommer, Director Ejecutivo y Analista de Investigación de Acciones Senior en Morgan Stanley.
La conferencia está programada para el miércoles 4 de septiembre de 2024 a las 5:35 PM ET. Los inversores y partes interesadas pueden acceder a una transmisión de audio en vivo del evento a través de la sección 'Inversores/Eventos' en el sitio web de IDEAYA o a través del anfitrión de la conferencia. La repetición de la transmisión estará disponible durante 30 días después del evento en vivo, ofreciendo la oportunidad a quienes no pudieron asistir para ponerse al día con la discusión.
IDEAYA Biosciences (NASDAQ: IDYA)는 정밀의학 종양학 회사로 모건 스탠리 제22회 연례 글로벌 헬스케어 콘퍼런스에 참여한다고 발표했습니다. 이 행사에서는 유지로 S. 하타 IDEAYA CEO와의 대담이 진행되며, 모건 스탠리의 전무 이사이자 수석 주식 연구 분석가인 주다 프롬머가 진행합니다.
콘퍼런스는 2024년 9월 4일 수요일 오후 5시 35분 ET에 예정되어 있습니다. 투자자 및 관심 있는 분들은 IDEAYA 웹사이트의 '투자자/이벤트' 섹션이나 콘퍼런스 호스트를 통해 이벤트의 실시간 오디오 웹캐스트에 접근할 수 있습니다. 웹캐스트 재방송은 라이브 이벤트 후 30일 동안 제공되어 참석하지 못한 분들이 논의를 따라잡을 수 있는 기회를 제공합니다.
IDEAYA Biosciences (NASDAQ: IDYA), une entreprise de médecine de précision en oncologie, a annoncé sa participation à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. L'événement comprendra une discussion informelle avec Yujiro S. Hata, CEO d'IDEAYA, animée par Judah Frommer, Directeur Exécutif et Analyste Senior en Recherche d'Actions chez Morgan Stanley.
La conférence est prévue pour mercredi 4 septembre 2024 à 17h35 ET. Les investisseurs et les parties intéressées peuvent accéder à un webinaire audio en direct de l'événement via la section 'Investisseurs/Événements' du site web d'IDEAYA ou par l'intermédiaire de l'hôte de la conférence. La rediffusion du webinaire sera disponible pendant 30 jours après l'événement en direct, offrant ainsi une opportunité à ceux qui n'ont pas pu assister de rattraper la discussion.
IDEAYA Biosciences (NASDAQ: IDYA), ein Unternehmen für präzisionsmedizinische Onkologie, hat seine Teilnahme an der 22. Morgan Stanley Global Healthcare Conference angekündigt. Die Veranstaltung wird ein Kamin-Gespräch mit Yujiro S. Hata, CEO von IDEAYA, beinhalten, das von Judah Frommer, Executive Director und Senior Equity Research Analyst bei Morgan Stanley, moderiert wird.
Die Konferenz ist für Mittwoch, den 4. September 2024 um 17:35 Uhr ET angesetzt. Investoren und interessierte Parteien können über den Bereich 'Investoren/Ereignisse' auf der IDEAYA-Website oder über den Gastgeber der Konferenz auf einen Livestream zugreifen. Die Wiederholung des Livestreams steht 30 Tage nach der Live-Veranstaltung zur Verfügung und bietet so eine Möglichkeit für diejenigen, die nicht teilnehmen konnten, um die Diskussion nachzuholen.
- None.
- None.
Morgan Stanley 22nd Annual Global Healthcare Conference
Wednesday, September 4th, 2024 at 5:35 PM ET
- Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Judah Frommer, Executive Director, Senior Equity Research Analyst
A live audio webcast of the conference event, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-the-morgan-stanley-22nd-annual-global-healthcare-conference-302229732.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) participating in the Morgan Stanley Healthcare Conference?
Who will represent IDEAYA Biosciences (IDYA) at the Morgan Stanley Healthcare Conference?
How can investors access IDEAYA Biosciences' (IDYA) presentation at the Morgan Stanley conference?
How long will the replay of IDEAYA Biosciences' (IDYA) Morgan Stanley conference presentation be available?
